A cutting-edge base-edited CAR T-cell therapy is opening a revolutionary new frontier for patients battling aggressive T-cell ...

A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) ...

Researchers headed by a team at Seattle Children’s Research Institute have shown for the first time that engineered human plasma B cells can be used to treat a disease—more specifically leukemia—in a ...

Researchers show for the first time that engineered human plasma B cells can be used to treat a disease—specifically leukemia—in a humanized animal model. The results mark a key step in the ...

SHANGHAI, Oct. 19, 2025 /PRNewswire/ -- Primary plasma cell leukemia (pPCL) is a rare and highly aggressive plasma cell malignancy, often associated with complex genetic abnormalities. There is ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell ...

Scientists at the University of Washington have engineered human plasma B cells modified to express long-lasting bispecific antibodies that could be used to treat leukemia without requiring continuous ...

A team of researchers at the Icahn School of Medicine at Mount Sinai has uncovered why children with the same ...